Non Hodgkin's lymphoma (NHL): Support a clinical trial to improve treatment
Last updated: 12/09/2012
What’s this project about?
Non-Hodgkin’s lymphoma (NHL) is the fifth most common cancer in the UK, with more than 10,700 people diagnosed with the disease every year.
Professor Andrew Pettitt is carrying out a clinical trial, PACIFICO, to improve the treatment of older people with follicular lymphoma - the results of which could lead to a change in the way patients are treated in the future, helping to improve survival from the disease while minimising side effects.
Find out more in the new video, and hear about Carole's experience on the trial.
Read the video transcript here.
Supporting this project
Anonymous donatedIn Memory of my dear Husban... In Memory of my dear Husband +in the hope that research will lead to more successful treatment. more
Stephen donatedFor the family and in memor... For the family and in memory of Shirley Coates from Simon and Stephen Perkins more
Anonymous donatedIn memory of Shirley
Let your friends and family know about this project to get them involvedShare this project
Project update - March 2011
Professor Pettitt shared some updates with us - read on to find out the latest with PACIFICO.
The PACIFICO trial has made very good progress. Recruitment has gone really well since Christmas and we also have growing number of participating centres.
Not only will the trial results help us to understand the best type of chemotherapy to use in people with follicular lymphoma, but the samples we collect will form a unique and extremely important resource for scientists. These can be used in their laboratory research to understand more about the disease and its treatment.
What’s the science behind the project?
Currently, doctors use a combination of three different chemotherapy drugs along with an antibody called rituximab as the ’gold standard’ treatment for patients over the age of 60 with follicular lymphoma, the most common type of NHL.
Although this treatment usually works fairly well, it is possible that using an even more potent cocktail of chemotherapy could be more effective.
But the major drawback is that giving people more aggressive chemotherapy tends to cause more damage to the body and therefore more side effects, which can especially be a problem for older people whose bodies can be less able to cope.
Professor Andrew Pettitt is leading a clinical trial called PACIFICO that will compare the current standard chemotherapy treatment with a newer, more potent, combination of drugs.
At the end of the trial, the results will be analysed to find out which of the two combinations achieves the best balance between effectiveness and impact on the patients’ quality of life.
If the new combination of drugs is more effective than the current treatment and doesn’t cause unacceptable side effects, it will become the new ’gold standard’ treatment, improving survival for this group of patients in the future.
The difference you can make
Although survival rates for non-Hodgkin’s lymphoma have improved over the last 30 years, around 4,500 people still die of the disease each year in the UK.
We urgently need to find more effective ways to treat the disease so that more patients survive in the future. Please help us raise £100,000 to support the running costs of this trial for a year.
Donate now and you can help support: Non Hodgkin's lymphoma (NHL): Support a clinical trial to improve treatment